European court rules Teva, Cephalon must pay $60M fine for reverse payment scheme after failed appeal
Teva and its subsidiary Cephalon’s hopes that a European court would dismiss or reduce more than $60 million in fines have been dashed after the court ruled against it yesterday in a case that accused the companies of conspiring in a pay-for-delay scheme.
Back in 1997, Cephalon started selling its sleep disorder drug Provigil (modafinil) in the UK and then several other countries by 2005. As patents for the drug were about to expire, Cephalon created a second generation drug called Nuvigil with plans to create another called Sparlon, both based on the active ingredient modafinil.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.